PROLOCOR
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases. The company's goal is to develop a more precise method and diagnostic tool for assessing and managing risk in cardiovascular disease. Prolocor was founded in 2020 and is based in Philadelphia, PA.
PROLOCOR
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2020-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.prolocor.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
6.9 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager Google Analytics Global Site Tag Google Analytics 4 Cloudflare JS CDN JS
Similar Organizations
BillionToOne
BillionToOne is a precision diagnostics company focused on genetic testing for disease detection.
Cardurion Pharmaceuticals
Cardurion is a Boston-based cardiovascular biotechnology company
Catalym
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Clarapath
We are a medical robotics company developing the SectionStar, a platform to mimic the human histotechnician.
Heartbeat Health
Heartbeat Health is a healthcare technology company that delivers virtual-first cardiovascular disease prevention and management.
Natera
Natera specializes in cell-free DNA testing to elevate the science and utility of prenatal testing.
Octagos Health
Octagos Health is a digital health company focused on remote monitoring of cardiac devices.
Quest Diagnostics
Quest Diagnostics is a clinical laboratory that offers diagnostic testing, services, and information.
Senti Biosciences
Senti Biosciences is a developer of a programmable biology platform for cancer therapies.
Valneva
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Current Employees Featured
Founder
Investors List
LabCorp Venture Fund
LabCorp Venture Fund investment in Convertible Note - Prolocor
Green Park & Golf Ventures
Green Park & Golf Ventures investment in Convertible Note - Prolocor
Green Park & Golf Ventures
Green Park & Golf Ventures investment in Seed Round - Prolocor
LabCorp
LabCorp investment in Seed Round - Prolocor
Small Business Innovation Research
Small Business Innovation Research investment in Grant - Prolocor
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-11 | Prolocor Announces Appointment of Raymond Russo as Chief Commercial Officer |
Official Site Inspections
http://www.prolocor.com Semrush global rank: 8.95 M Semrush visits lastest month: 445
- Host name: vps68528.inmotionhosting.com
- IP address: 70.39.251.123
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Prolocor"
Who We Are - Prolocor
We are assembling a team of experienced scientists, clinicians, and industry leaders with experience in cardiovascular medicine, patient care, and diagnostics. Pete co-founded …See details»
Prolocor - Crunchbase Company Profile & Funding
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases. Prolocor may be growing as it has recently secured $1.7 million in bridge funding, which suggests an influx of capital that can be used …See details»
Prolocor Company Profile 2024: Valuation, Funding & Investors
Prolocor has raised $4.9M. Who are Prolocor’s investors? Green Park & Golf Ventures , Labcorp Venture Fund , Laboratory Corporation of America , National Heart, Lung, and Blood Institute, …See details»
Prolocor - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised ... obfuscated. Green Park & Golf Ventures: Aug …See details»
Prolocor - Products, Competitors, Financials, Employees, …
About Prolocor. Prolocor is a company focused on the healthcare sector, specifically in the domain of cardiovascular disease diagnostics. The company's main offering is an innovative …See details»
PROLOCOR INC. Company Profile | Philadelphia, PA | Competitors ...
Find company research, competitor information, contact details & financial data for PROLOCOR INC. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
Prolocor - Contacts, Employees, Board Members, Advisors & Alumni
Prolocor has 3 current employee profiles, including Co-Founder & CSO David Schneider. David Schneider Co-Founder & CSO Peter M. DiBattiste CEO, Co-Founder & PresidentSee details»
Prolocor Announces a Combined $5.2 Million in Funding From …
Aug 16, 2022 Prolocor Logo Prolocor Logo PHILADELPHIA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Prolocor, Inc., a healthcare startup developing an innovative precision …See details»
Prolocor Announces a Combined $5.2 Million in Funding From
Aug 16, 2022 Prolocor also announced the receipt of a $2 million Phase II grant from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH).See details»
Prolocor
[email protected]. A novel diagnostic test to quantify FcyRIIa on the surface of platelets. Let's scratch the surface. In the United States, atherosclerotic cardiovascular disease is a leading …See details»
What We Do - Prolocor
[email protected]. What We Do. problem. CV disease is the leading cause of death and disability around the world 1. USA. 20000000. adults have coronary artery disease (CAD) 2. …See details»
Prolocor Makes Case for Cardiovascular Risk Test in New …
Nov 14, 2024 Prolocor is planning a pilot launch of the assay to start because it needs to prove that there is "a real demand for this test," that the company can operationalize the test, and …See details»
Prolocor Announces a Combined $5.2 Million in Funding From
PHILADELPHIA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the...See details»
Prolocor Announces Publication of Confirmatory Results From …
Oct 21, 2024 Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death ; Significant unmet need in balancing the risks and benefits of antithrombotic treatment in …See details»
How We Do It | Prolocor
[email protected]. How We Do It. our approach. Our approach is guided by our vision to advance patient care, by empowering the healthcare community with effective precision …See details»
Prolocor Announces Publication of Confirmatory Results From …
Oct 21, 2024 Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death Significant unmet need in balancing the risks and benefits of antithrombotic treatment in …See details»
Newsroom - Prolocor
Feb 9, 2023 Prolocor presented at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference. read more. SEE MORE EVENTS. …See details»
Prolocor Announces Publication of Confirmatory Results From …
Oct 21, 2024 PHILADELPHIA, PA / ACCESSWIRE / October 21, 2024 / Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCG® test that identifies …See details»
Prolocor
Reach out to us via email. [email protected]. connect with usSee details»